# **Research** Paper

# Intelligent Biosynthetic Nanobiomaterials (IBNs) for Hyperthermic Gene Delivery

Tze-Haw Howard Chen,<sup>1</sup> Younsoo Bae,<sup>1</sup> and Darin Y. Furgeson<sup>1,2,3</sup>

Received February 2, 2007; accepted June 18, 2007; published online August 29, 2007

**Purpose.** Intelligent biosynthetic nanobiomaterials (IBNs) were constructed as recombinant diblock copolymers, notated as  $K_8$ -ELP(1–60), containing a cationic oligolysine (VGK<sub>8</sub>G) and a thermosensitive elastin-like polypeptide (ELP) block with 60 repetitive pentapeptide units [(VPGXG)<sub>60</sub>; X is Val, Ala and Gly in a 5:2:3 ratio].

*Methods.*  $K_8$ -ELP(1–60) was synthesized by recursive directional ligation for DNA oligomerization. Purity and molecular weight of  $K_8$ -ELP(1–60) were confirmed by SDS-PAGE and mass spectrometry. DNA polyplexes were prepared from  $K_8$ -ELP(1–60) and pGL3-Control (pGL3–C) plasmid DNA (pDNA) and stability was evaluated by gel retardation, DLS, and DNA displacement with heparin. Thermal transition profiles were studied by measuring the turbidity change at 350 nm and the polyplexes were used to transfect MCF-7 cells with a concomitant cytotoxicity assay.

**Results.** SDS-PAGE and MALDI-TOF studies showed highly pure copolymers at the desired molecular weight.  $K_8$ -ELP(1-60) condensed pDNA at a cation to anion (N/P) ratio above 0.25 with a tight distribution of particle size ranging from 115.5–32.4 nm with increasing N/P ratio. Thermal transition temperatures of  $K_8$ -ELP(1-60)/pDNA and  $K_8$ -ELP(1-60) alone were 44.9 and 71.5°C, respectively.  $K_8$ -ELP(1-60)/pDNA complexes successfully transduced MCF-7 cells with qualitative expression of enhanced green fluorescent protein (EGFP) and minimal cytotoxicity compared to branched poly(ethyleneimine) controls.

**Conclusions.**  $K_{s}$ -ELP(1-60) was successfully designed and purified through recombinant means with efficient and stable condensation of pDNA at N/P ratios>0.25 and polyplex particle size<115 nm. MCF-7 cells successfully expressed EGFP with minimal cytotoxicity compared to positive controls; moreover, polyplexes retained sharp, thermotransitive kinetics within a narrow  $T_t$  range at clinically relevant hyperthermic temperatures, where the decrease of  $T_t$  was due to the increased hydrophobicity upon charge neutralization.

**KEY WORDS:** nanobiomaterial; intelligent polymer; elastin-like polypeptide; gene delivery; gene vector; hyperthermia.

# INTRODUCTION

As a model molecular medicine, gene therapy continues to show great promise for monomodal treatment of acute and chronic diseases (1,2), deleterious genetic predispositions (3), and additive or synergistic combination therapies with classical regimens, such as hyperthermia (4). The success of nonviral gene therapy depends largely upon the performance

<sup>1</sup> Division of Pharmaceutical Sciences, School of Pharmacy, University of Wisconsin—Madison, Madison, Wisconsin 53705-2222, USA.

<sup>2</sup> Department of Biomedical Engineering, University of Wisconsin-Madison, Madison, Wisconsin 53705-2222, USA. of delivery vectors to protect plasmid DNA (pDNA) in an active form by controlling its condensation and decondensation in sufficient numbers to elicit a therapeutic effect. Initially, viruses would appear to be the most efficient vectors; however, viral-based systems commonly compromise biocompatibility, patient safety, and induce high costs of scale-up. As such, nonviral approaches have emerged as an attractive alternative represented largely as artificial cationic formulations (5,6), liposomes (7,8), and polymers (9,10). Among these formulations, polymers are considered the most receptive for facile modification with various substituents or by block copolymerization. For example, recent studies have shown that poly(ethylene glycol) (PEG)-poly (L-lysine) (PLL) conjugated cationic block copolymers effectively condense pDNA into a core-shell polyion complex (PIC) micelle structure and reduce the toxicity of cationic polymers alone (11). Polymer PEGylation prevents hydrophobic aggregation by steric repulsion of polycation/pDNA complexes and clearance by the reticuloendothelial system (RES). Regarding the cationic block, it has been revealed

<sup>&</sup>lt;sup>3</sup> To whom correspondence should be addressed. (e-mail: dfurgeson@ pharmacy.wisc.edu)

**ABBREVIATIONS:** ELP, elastin-like polypeptide; ELP(1–60), ELP with 60 repetitive pentapeptide units [(VPGXG)<sub>60</sub>, X is Val, Ala and Gly in a 5:2:3 ratio]; IBN, intelligent biosynthetic nanobiomaterial; ITC, inverse transition cycling;  $K_8$ , oligolysine (VGK<sub>8</sub>G); RDL, recursive directional ligation; T<sub>t</sub> (°C), phase transition temperature.

that the selection of optimal compositions such as molecular weight and pKa plays a pivotal role in facilitating the release and endosomal escape of pDNA (12,13) and eventually induces high transfection efficiency.

The synthesis of functional cationic block copolymers, however, is not simple and often requires specialized polymer chemistry. In particular, it is obvious that the gross physicochemical properties of synthesized polymers, such as molecular weight, polydispersity, reaction ratios, etc., are prone to changes between batches. Furthermore, more sophisticated chemistry becomes necessary for modification of block polymers with targeting ligands or implementation of new functionalities, consequently imposing a bottleneck for continued development by these complexities alone. In this study, we report a novel intelligent biosynthetic nanobiomaterial (IBN) platform for multi-targeted nonviral gene therapy. Thermosensitive cationic diblock copolymers were designed and synthesized for gene delivery through recombinant DNA cloning technology based upon recursive directional ligation (RDL), a facile biosynthetic route achieved by conventional bacterial culture expression (14). Block copolymers were composed of a cationic block from oligolysine (VGK $_8$ G) and a thermosensitive elastin-like polypeptide (ELP) block with 60 repetitive pentapeptide units [(VPGXG)<sub>60</sub>; X is Val, Ala and Gly in a 5:2:3 ratio], notated as  $K_8$  and ELP(1-60), respectively. It must be clarified that K<sub>8</sub> and ELP(1-60) were selected herein as model blocks to exemplify our hypotheses that functional cationic diblock copolymers can be synthesized through biosynthesis with a high purity and yield at the precise molecular weight and the biosynthesized diblock copolymers composed of hydrophilic and cationic blocks would condense, protect, and transfer pDNA similar to PEGylated polycation formulations for gene delivery. It also should be noted that an oligolysine block was used instead of a cationic elastin block, where the guest residue X is replaced with lysine. Although a cationic elastin block (VPGKG)<sub>n</sub> has previously been developed (15), the cationic charge density is significantly lower compared to an oligolysine block; furthermore, polyplex assembly with such a system may be compromised as a result of steric interference. Hence, a (K<sub>8</sub>) oligolysine block was selected to promote DNA condensation based on the concern over charge density and the polymer's DNA condensing ability (16,17).

The significance of ELPs as useful thermosensitive biomaterials was originally suggested by Urry (18) and has been extensively studied by the pioneers of biopolymers in the last decade. Briefly, ELP libraries are composed of Val-Pro-Gly-Xaa-Gly (VPGXG) pentapeptide monomers, where "X" is any guest residue other than Pro (19). ELPs are characterized by high water-solubility, biocompatibility (20-22), and a reversible, rapid response to temperature with an inverse temperature phase transition (23). The rapid inverse temperature phase transition  $(T_t)$  is a function of the type and degree of guest residue (X) substitution, ionic state, and molecular weight (24) amongst other factors. Indeed, ELPs are highly soluble in aqueous solutions below the T<sub>t</sub> but rapidly aggregate above the T<sub>t</sub>. Furthermore, as this phase transition is completely reversible, ELPs may be used as a thermosensitive carrier for the delivery of therapeutic agents (25,26). This innate characteristic

presents an opportunity for hyperthermic targeting of materials conjugated or associated with ELP following local or systemic administration and has been exploited to deliver drugs to solid tumors or *in situ* (27). *In vivo* studies also showed that cellular uptake and accumulation of ELPs in tumor tissues increased two fold with hyperthermia (28). Furthermore, it has been shown that by fusing cell penetration and therapeutic peptides, ELPs can deliver therapeutic cargos intracellularly with enhanced antiproliferative effects attributed to the ELP hyperthermic response (29,30).

DNA cloning technology has gained increasing attention as a novel tool for nonviral gene delivery vector preparation in the past few years, owing to its ability of creating structurally well-defined materials (31). The inherent characteristics of these biomaterials allow the study of desired properties for successful biosynthetic gene delivery vectors via a structure-function relationship difficult to achieve by synthetic polymers and hence the impetus for IBN platforms. Arís et al. (32) reported the first stable oligolysine encoding fusion protein, β-galactosidase, prepared by DNA cloning technology for gene delivery. The fusion protein consists of an N-terminal oligolysine domain for DNA condensation and an arginine-glycine-aspartic acid (RGD) sequence inserted on a solvent exposing loop of the protein for integrin targeting. In another report by Medina-Kauwe et al. (33), an oligolysine domain was cloned to the Cterminus of an adenoviral penton protein, showing 13% of transgene activity compared to lipofectin. Moreover, lysinehistidine (KH) repeats fused to basic fibroblast growth factor (bFGF) were prepared by Hatefi et al. (34) and showed enhanced transfection compared to KH repeats alone. It is of special note that to our knowledge, only the retated silk elastinlike polymers (SELP) pioneered by Ghandehari et al. have been investigated for matrix-mediated naked DNA and adenoviral gene therapy (35,36). However, there are no reports of systemic gene delivery utilizing thermosensitive ELP. Hyperthermic gene transfer by thermoresponsive polymers with enhanced transgene expression has been reported previously (37,38). Zintchenko et al. attributed the enhanced expression to an elevated "proton sponge" effect elicited by the large numbers of branched poly(ethyleneimine) (BPEI)-bpoly(N-isopropylacrylamide) (PNIPAM) copolymer molecules presenting in the endosome with hyperthermia. This phenomenon was hypothesized as the large, aggregated particles were internalized by cells at elevated temperature. This same mechanism could also enhance transfection efficiency with K<sub>8</sub>-ELP(1-60) allowing endosomal buffering capability; however, this hypothesis is currently being rigorously studied.

On this basis, we designed IBNs as cationic proteinbased diblock copolymers for systemic gene therapy containing electrostatically condensing oligolysine blocks and thermosensitive, particle stabilizing ELP blocks for systemic gene therapy. Herein we report the synthesis and characterization of  $K_8$ -ELP(1–60) block copolymers as a novel formulation for the development of thermosensitive nonviral gene vectors, an extension of the IBN platform. The evaluation was focused on the feasibility of  $K_8$ -ELP(1–60) and its DNA complexes for practical application in hyperthermic gene therapy.

# **MATERIALS AND METHODS**

#### Materials

E. coli strain BLR(DE3) and Top10 cells were purchased from Novagen (Madison, WI) and Invitrogen (Carlsbad, CA), respectively. T4 DNA ligase, restriction enzymes, and pUC19 cloning vectors were obtained from New England Biolabs (Beverly, MA). Calf intestinal alkaline phosphatase (CIP), pGL3-C plasmid, and the CellTiter-Glo kit were obtained from Promega (Madison, WI). The pET-25b(+)SV2 and pUC19-ELP(1-30) plasmids were kindly gifted by Prof. Ashutosh Chilkoti (Duke University, Dept. of Biomedical Engineering). Large-scale DNA preps were conducted using PureLink<sup>TM</sup> Plasmid Filter Maxiprep Kits from Invitrogen (Carlsbad, CA). CircleGrow culture medium was purchased from Q-BIOgene (Carlsbad, CA). 5'-Phosphorylated oligonucleotides were synthesized at the UW-Madison Biotechnology Center. Precast Mini-Protein SDS-PAGE gels were purchased from BioRad, Inc. (Hercules, CA). Dulbecco's modified eagle medium (DMEM) and fetal bovine serum (FBS) were obtained from Mediatech, Inc. (Herndon, VA). BPEI and heparin sodium were purchased from Sigma (St. Louis, MO).

#### Gene Construction for Diblock Copolymers

The forward and reverse DNA sequences of VGK8G AGAAAGGC-3' and 5'-TTTCTTTTTTTTTTTTTTTTTTTTTTTT TACCCACGCC-3', respectively. Oligonucleotides were annealed to form a double-stranded DNA cassette with PflM I compatible ends by heating an equimolar mixture of two oligonucleotides at 95°C for 5 min followed by slow cooling (1°C/min) to room temperature. pUC19-ELP(1-30) was digested with PflM I and enzymatically dephosphorylated using CIP. The linearized pUC19-ELP(1-30) vector was separated by low melting agarose gel electrophoresis and purified by a QIAGEN (Valencia, CA) QIAquick gel extraction kit. The annealed oligonucleotides and linearized vector were ligated at 16°C for 18 h. The ligation mixture was combined with 100 µl of chemically competent Top10 cells, transformed by heat shock, spread on CircleGrow medium agar plates supplemented with ampicillin (100 µg/ml), and incubated at 37°C overnight. Later, multiple colonies were chosen and grown further in 3 ml CircleGrow medium at 37°C for 12 h. Plasmids were isolated and purified using a Qiagen Miniprep kit. DNA sequencing and diagnostic digestion of the purified plasmids were performed using EcoR I and Hind III to confirm the putative insert. The K<sub>8</sub>-ELP(1-30) encoded plasmid was doubly digested with PffM I and Bgl I and the resulting insert was gel purified. To obtain the K<sub>8</sub>-ELP(1-60) gene, the K<sub>8</sub>-ELP(1-30) insert was ligated into the linearized pUC19-ELP(1-30) vector, and the resulting clones were screened following the above protocol. The pET-25b(+)SV2 expression vector was modified by cassette mutagenesis further referenced as pET-25b(+)HC1. The forward and reverse DNA sequences of this cassette were 5'-TATGAGCGGGCCGGGGCTGGCCGTGATA-3' and 5'-AGCTTATCACGGCCAGCCCGGCCCGCTCA-3', respectively. This cassette contains an Sfi I restriction site with

flanking sequences compatible with *PfI*M I and *BgI* I digested inserts. Oligonucleotides were annealed by heating an equimolar mixture at 95°C for 5 min and then slowly cooled (1°C/min) to room temperature to form a double-stranded DNA cassette with *Nde* I and *Hind* III compatible ends. The cassette was inserted into the *Nde* I and *Hind* III restriction sites by restriction enzyme digestion and ligation. The resulting plasmid was confirmed by DNA sequencing. The pET-25b(+)HC1 was digested with *Sfi* I and enzymatically dephosphorylated using CIP followed by gel purification. *PfI*M I and *BgI* I digested K<sub>8</sub>-ELP(1–60) was then ligated into the linearized pET-25b(+)HC1. Cloning was confirmed by diagnostic digestions using *Ava* I and *Xba* I. The plasmid containing the correct insert gene was transformed into the *E. coli* BLR (DE3) strain by heat shock.

# Expression and Purification of the K<sub>8</sub>-ELP(1–60) Diblock Copolymer

The K<sub>8</sub>-ELP(1-60) diblock copolymers were expressed in E. coli BLR(DE3) at 37°C for 24 h on an orbital shaker at 225 rpm. The polymers were purified from the E. coli according to the inverse transition cycling (ITC) method described elsewhere (14) except that two rounds of PEI precipitation were used to remove any traces of chromosomal DNA. The concentration of the  $K_8$ -ELP(1-60) diblock copolymer solution was determined by UV spectrophotometry using a molar extinction coefficient of 5,690/M·cm at 280 nm. Purified polymers were characterized by SDS-PAGE and mass spectrometry to confirm purity and molecular weight. The polyacrylamide gel was visualized by Coomassie Blue staining. The molecular weight of the polymer was confirmed by electrophoresis comparing the corresponding band to a molecular weight standard and further verified by MALDI-TOF mass spectrometry.

# Agarose Gel Electrophoresis of K<sub>8</sub>-ELP(1–60)/pDNA Polyplexes

In order to confirm the ability of the polymers to condense pDNA,  $K_8$ -ELP(1–60)/pDNA polyplexes with various N/P ratios were electrophoresed on agarose gels. Variable concentrations of  $K_8$ -ELP(1–60) in phosphate buffered saline (PBS) were added to equal volume of 1 µg pGL3-C in PBS at room temperature to prepare the polyplexes while the N/P ratios were adjusted from 0.05 to 5. Electrophoresis was performed at 4°C on a 0.8% high melting agarose gel at 100 V for 90 min and visualized by ethidium bromide staining at a final concentration of 0.4 µg/ml.

# Thermal Characterization of the Inverse Temperature Phase Transition

In order to measure the  $T_t$  of the complexes,  $K_8$ -ELP (1–60) was dissolved in PBS at 50  $\mu$ M and 350  $\mu$ l of the polymer solution was added to equal volumes of DNA solution at room temperature with various concentrations to adjust the N/P ratio. After incubation at 25°C for 30 min, 600  $\mu$ l of the complex solution were subjected to the thermal transition study, which the optical density was monitored at 350 nm as a function of temperature using a Cary 100 UV-

visible spectrophotometer equipped with a multicell thermoelectric temperature controller (Varian, Inc., Palo Alto, CA). The rate for heating and cooling temperatures was 1°C/min and the  $T_t$  was determined as the temperature that exhibits half of the maximum optical density.

# Sizes of K<sub>8</sub>-ELP(1-60)/pDNA Polyplexes

The particle size of  $K_8$ -ELP(1–60)/pDNA polyplexes was determined by dynamic light scattering (DLS) measurements (NICOMP 380 ZLS instrument, Particle Sizing Systems, Santa Barbara, CA). Twenty-five micromolar polyplexes were prepared as described above, while the N/P ratio was adjusted from 1 to 10. Samples were prepared in triplicate to produce statistical parameters.

## In Vitro pDNA Release Assay

The pDNA release profile of  $K_8$ -ELP(1–60)/pDNA polyplexes was evaluated by electrophoresis after mixing stable polyplexes with heparin for polyanion displacement. Polyplexes at N/P 1 were prepared at a final pDNA concentration of 50 µg/ml and 200 µl final volume. After incubation at 25°C for 30 min, 15 µl of the polyplex solution were transferred to 12 micro tubes and mixed with 15 µl of heparin solution at various concentrations. The mixed solutions were incubated at 25°C for another 30 min and then 20 µl of the solution were electrophoresed.

# Cytotoxicity Assay

MCF-7 cells (human breast cancer) were seeded in 24well plates at an initial density of 50,000 cells per well. The cells were preincubated at 37°C in a 5% CO<sub>2</sub> humidified atmosphere in 1 ml of DMEM containing 10% FBS and 1% penicillin/streptomycin for 24 h. Twenty microliters of the polyplex solution were pre-mixed with 179 µl of serum free DMEM containing 1% penicillin/streptomycin and 1 µl 20 mM chloroquine; 20 µl of the native copolymer solution were



Fig. 1. The chemical structure of biosynthesized  $K_8$ -ELP(1–60) diblock copolymers and preparation of intelligent thermosensitive nonviral gene vectors.

pre-mixed with 180  $\mu$ l of serum free DMEM containing 1% penicillin/streptomycin, both solutions were then applied to the cells after the initial medium had been removed. After a 4 h incubation at 37°C, the medium was discarded and the cells were washed twice with PBS followed by adding fresh medium. The cells were incubated for another 20 h with serum containing DMEM and the viability of the cells was determined by a CellTiter-Glo kit.

#### In Vitro Transfection Study

MCF-7 cells were seeded in 24-well plates at an initial density of 50,000 cells per well. After cells were incubated until 70% confluent, 20  $\mu$ l of polyplex solution were premixed with 179  $\mu$ l of serum free DMEM containing 1% penicillin/streptomycin and 1  $\mu$ l 20 mM chloroquine to facilitate ensonomal release. The initial medium was removed and the polyplex solutions were added to the cells. The cells were incubated for 4 h at 37°C after which the experimental medium was removed, cells washed twice with PBS, and fresh medium containing 10% serum was added. Cells were incubated for another 20 h before GFP gene expression was visualized.

#### Statistical Analysis

Groups were compared simultaneously by one-way ANOVA and Bonferroni post-test. Data were deemed statistically significant at p<0.01.

# RESULTS

#### Gene Construction and Polymer Expression

The  $P_{fl}M$  I compatible ends were introduced to the  $K_8$ encoding oligonucleotides to clone the pUC19 vector encoding the ELP(1-30) gene. RDL was then used for the extension of the ELP1 gene by DNA oligomerization (14). The K<sub>8</sub> gene was cloned into the vector prior to propagation of the ELP1 gene. This step facilitated the separation of the original ELP1 gene and the  $K_8$ -ELP(1-60) gene with a short K<sub>8</sub> block by diagnostic digestion and gel electrophoresis. The gene for the  $K_8$ -ELP(1-60) copolymer was then subcloned into the pET25b(+)HC1 vector, and the copolymers were expressed in the E. coli strain BLR(DE3). K<sub>8</sub>-ELP(1-60) block copolymers (Fig. 1) were purified from the cell lysate by ITC with a yield of 17 mg/l. As shown in Fig. 2, sonicated cells were purified by centrifugation of the cell lysate to collect supernatant (Lane 2); PEI adding to the supernatant to remove chromosomal DNA contaminants (Lane 3); centrifugation at T>T<sub>t</sub> of ELP to separate supernatant (Lane 4) and ELP (Lane 5); repeating hot-spin to remove impurities in the supernatant (Lane 6); and purified ELP (Lane 7). Molecular weights of the obtained ELPs were compared with the standard (Lane 8). Surprisingly, SDS-PAGE showed the molecular weight of  $K_8$ -ELP(1–60) to be higher (ca. 35 kDa) than the expected 25 kDa, a phenomenon commonly observed in small, repetitive amino acids. Indeed, a MALDI-TOF mass spectrometry clearly showed the molec-



**Fig. 2.** SDS-PAGE at different purification stages. (Lanes 1 and 8) with a molecular weight marker from 10 - 190 kDa; (Lane 2) sonicated cell lysate; (Lane 3) supernatant collected after PEI precipitation; (Lane 4) supernatant collected after the first hot spin; (Lane 5) pellet collected after the first hot spin; (Lane 6) supernatant collected after the second hot spin; and (Lane 7) purified  $K_8$ -ELP(1-60) diblock copolymers collected after the second hot spin. SDS-PAGE with a 4-20% gradient polyacrylamide gel at 100V., for 150 min. The gel was then stained by Coomasive Blue.

ular weight of K<sub>8</sub>-ELP(1–60) was 25,317 Da (Fig. 3) with an expected result of 25,445 Da. A previous report showed the difference could be attributed to the removal of the N-terminal methionine by methionyl-aminopeptidase (39). The relatively low yield compared to the general yields for ELP1 homopolymer (>200 mg/l) is probably due to copolymer loss during ITC as a result of the cationic K<sub>8</sub> block's effect on increasing the thermotransition of the block copolymers.



**Fig. 3.** Molecular weight distribution of  $K_8$ -ELP(1-60) diblock copolymers measured by MALDI-TOF mass spectrometry. The expected M.W. was 25445 kDa, which was different from the 25317 kDa observed M.W. possibly due to the *N*-terminal methionine deletion (39).



Fig. 4. Gel retardation assay of cationic elastin diblock copolymers and pDNA. Gel conditions were 0.8% high melting agarose, 100V, 90 min, and 0.4  $\mu$ g/ml ethidium bromide.

# Preparation and Characterization of K<sub>8</sub>-ELP(1–60)/pDNA Polyplexes

Gel retardation assays show that K<sub>8</sub>-ELP(1-60) condenses pDNA effectively (Fig. 4) at low N/P ratios. It is of special interest that pDNA condensation was shown at N/P 0.25 with EtBr exclusion at N/P 2.5 determined by EtBr staining. These results suggest that K<sub>8</sub>-ELP(1-60)/pDNA electrostatic interactions may not be the only driving force and that other cooperative effects, possibly hydrophobic, could be involved as the thermotransition profiles changed as the N/P ratios increased drastically (Fig. 5). The  $T_t$  of  $K_8$ -ELP(1-60) was 71.5°C at 25  $\mu$ M and considering that the T<sub>t</sub> of ELP(1-60) is 62.1°C (data not shown), it is suggested that the addition of the oligolysine moiety induced the increase in  $T_t$  as postulated by Urry (23) wherein polar amino acid side chains increase the T<sub>t</sub> of ELP polymers. As expected the T<sub>t</sub> of polyplexes at N/P 1 dropped to 44.9°C and the temperature range of the phase transition was narrow, suggesting a monodisperse system of electroneutral K<sub>8</sub>-ELP(1-60)/pDNA complexes, a cooperative hydrophobic effect might explain the lowering of the T<sub>t</sub> upon complex formation. The positive charges on the copolymers should neutralize the negative charges on pDNA, thus leaving the copolymers more hydrophobic relative to the native, protonated state; consequently, the resulting hydrophobicity may depress the  $T_t$ (40). It should be emphasized that this temperature  $(44.9^{\circ}C)$ is within clinically relevant temperatures for hyperthermic, adjuvant therapy (41). When the N/P ratios increased, however, the T<sub>t</sub> increased as expected and approached that of free  $K_8$ -ELP(1-60) (T<sub>t</sub> 71.5°C) with a corresponding depression of transition kinetics as shown by the broad transition curve. These results suggest a mixed population consisting of free K<sub>8</sub>-ELP(1-60) block copolymers combined with K<sub>8</sub>-ELP(1-60)/pDNA polyplexes at N/P>1. The  $T_t$  of polyplexes at N/P 10 was as high as that of free K<sub>8</sub>-ELP(1-60) block copolymers. Parallel DLS measurements (Table I) showed that the particle size of the polyplexes decreased from 115.5-32.4 nm as N/P ratios increased with a small rise at N/P 10. The sample groups were deemed statistically significant following one-way ANOVA and a Bonferroni post-test (p < 0.001). The size and distribution are promising in terms of in vivo systemic gene delivery applications. There-



Fig. 5. Thermal transition profiles of the native cationic elastin diblock copolymer and polyplexes at N/P ratios 1 to 10 at 25  $\mu$ M copolymer concentration. The heating rate was 1°C/min with turbidity monitored as OD<sub>350</sub>.

fore, it was concluded that  $K_8$ -ELP(1–60) block copolymers successfully condensed pDNA to form a nanoparticulated polyplex which shows clear thermosensitivity at proximal hyperthermic temperatures. Furthermore, neither turbidity nor physical aggregation was observed with  $K_8$ -ELP(1–60)/ pDNA polyplexes 30 minutes post formulation, which suggests a particle stabilization effect from the ELP similar to PEG.

# **DNA Release**

DNA release is essential for polyplexes to transfect cells, while stability of the polyplexes is a prerequisite to protect DNA. In order to evaluate the stability as well as the DNA releasing property of the polyplexes, heparin was mixed with  $K_8$ -ELP(1–60)/pDNA polyplexes in various concentrations (Fig. 6). There are a large number of anionic proteins in the body that may disrupt polyplexes, as such heparin is commonly used as a model anionic species to monitor DNA dissociation from polyplexes (42). Under assumed equilibrium conditions, stable polyplexes at N/P 1 were initially mixed with heparin at 0.019 USP units/µg DNA concentration. However, DNA release did not begin at heparin concentrations <0.19 USP units/µg DNA, and polyplexes were completely disrupted with pDNA release at 0.47 USP units heparin/µg DNA. Addition of 4–6 USP units of heparin/ml of whole blood is usually employed to prevent coagulation; therefore, these results indicate that the polyplexes were stable in the presence of anionic proteins (6 USP units of heparin/ml) corresponding to physiological conditions. The results suggest that  $K_8$ -ELP(1–60)/pDNA polyplexes may safely deliver and release its DNA cargo intracellularly.

#### **Observation of EGFP Transfection**

In order to assess the performance of  $K_8$ -ELP(1–60)/ pDNA polyplexes as a nonviral gene carrier, MCF-7 cells were transfected by polyplexes containing pEGFP-N3. As shown in Fig. 7, intense fluorescence of the enhanced green fluorescence protein (EGFP) was observed in the cells 24 h post transfection using polyplexes at N/P 1. Negative controls and naked pDNA did not show EGFP transgene expression. It must be mentioned that EGFP transfection was observed in limited cells while positive controls transfected large numbers of cells. While the positive transfection results are promising, there is substantial work to be done as these results show that transgene expression may be determined by cellular interactions such as exposure time, cell cycle, polyplex uptake, and thermal conditions.

# In Vitro Cytotoxicity

In vivo transfection is generally accompanied by longer exposure times at the targeted site than in vitro experimental conditions, hence it is of vital importance to assess cytotoxicity. Fig. 8 shows the cell viability against N/P ratios of the polyplexes where toxicities of the polyplexes were relatively low across all the N/P ratios tested. K<sub>8</sub>-ELP(1-60) block copolymers showed a concentration dependent cytotoxicity (Fig. 8), however, the cytotoxicity of the  $K_8$ -ELP(1–60) block copolymers is extremely low compared to PEI or PLL. At a 47.7 mg/ml copolymer concentration, nearly 72% of the cells were viable, which is in sharp contrast with less than 30% viable cells with the same concentration of PEI and PLL (43). Moreover, the relatively higher toxicity was induced presumably by the free cationic charge as evidenced by the results of increasing the N/P ratio. These results indicate that although free K<sub>8</sub>-ELP(1-60) block copolymers do induce cytotoxicity, this cytotoxicity is effectively neutralized with the formation of polyplexes.

Table I. Size Distribution of K<sub>8</sub>-ELP(1-60)/pDNA Polyplexes at N/P 1, 2.5, 5, and 10

	N/P ratios of the polyplexes			
	1	2.5	5	10
Hydrodynamic radius±SD (nm)	115.5±9.0	47.0±6.1	32.4±1.0	93.3±6.61

Hydrodynamic radius reported as mean±SD (n=3)



Fig. 6. DNA displacement by heparin sodium with  $K_8$ -ELP(1–60)/pDNA N/P 1 polyplexes.

#### DISCUSSION

Recombinant DNA cloning technology presages continued biosynthesis of polymers providing precise, genetic control over polymer structure and function for medicinal applications (31). Protein-based polymers, such as ELPs, are a class of such polymers with favorable properties for a wide range of biomedical applications; however, facile genetic engineering remains constrained by the available amino acids and host-strain expression. For example, expression of oligolysine ELP block copolymers could be difficult due to the repetitive amino acid block often flagged as deleterious by host organisms; moreover, oligo-lysine ELP may also pose a cytotoxic effect due to the high cationic charge, thereby destabilizing anionic membranes of organelles and/or cells. Yet despite these hurdles, success with lysine repeats is reported in the literature where fusion proteins containing



**Fig. 7.** Fluorescent micrograph of MCF-7 cells transfected with pEGFP: **a** non-treated cells; **b** naked pDNA; **c** BPEI/pDNA N/P 10; and **d** K<sub>8</sub>-ELP(1–60)/pDNA N/P 1. *Scale bar* represents 500 µm.



**Fig. 8.** Cytotoxicity of the polyplexes and native copolymers. The concentrations of native copolymers used in the study were the same as used in the polyplexes, which were 47.700, 119.25, 238.50, and 477.00  $\mu$ g/ml for N/P 1, 2.5, 5, and 10 respectively. Data reported as mean±SD (*n*=4).

oligo-lysines were successfully expressed in prokaryotic expression systems for gene transfer applications (32,33). Another interesting study was reported by Kiick et al. (44), which reported the incorporation of non-natural amino acids into biosynthetic polypeptides, further diversifying the application of polypeptides as functional materials. Herein we report for the first time IBNs consisting of cationic elastin diblock copolymers for multimodal gene therapy (Fig. 1). These gene carriers were designed for electrostatic pDNA condensation by the oligo-lysine block and contributing particle stability and thermal targeting by the ELP block. Results from SDS-PAGE and MALDI-TOF mass spectrometry showed that thermosensitive cationic block copolymers were successfully prepared with a high purity and precise molecular weight (Figs. 2 and 3), albeit at yields significantly lower than ELP homopolymers. Expression levels were most likely compromised by the high T<sub>t</sub> of the native cationic elastin diblock copolymers thereby limiting the effectiveness of ITC purification or perhaps compartmentalization by inclusion bodies, nevertheless, studies are ongoing to increase the yields. Surmising coulombic interactions between the anionic phosphate backbone of the pDNA and cationic oligo-lysine, pDNA condensation was observed at N/P 0.5 and near EtBr exclusion at N/P 2.5 (Fig. 4). As expected, particle size measurements of the K8-ELP(1-60)/ pDNA polyplexes decreased steadily from N/P 1 (~115 nm) to N/P 5 (~30 nm; Table I). K<sub>8</sub>-ELP(1-60)/pDNA polyplexes at N/P 10 increased in particle size presumably due to the presence of free or non-condensing K<sub>8</sub>-ELP(1-60) copolymers. Future study will include characterization by atomic

force microscopy, transmission electron microscopy, and determination of the critical association number to better elucidate the assertion that these polyplexes are micellar in structure.

For hyperthermic targeting of K<sub>8</sub>-ELP(1-60)/pDNA polyplexes, an appropriate thermotransitive profile is paramount. While native cationic block copolymers exhibited thermotransitive kinetics outside the range of clinically relevant hyperthermic temperatures, subsequent mixing with pDNA formed polyplexes with  $T_t \sim 45^{\circ}C$  (Fig. 5), which is proximal to clinically hyperthermic temperatures (37). Previous reports have shown that ELPs aggregate due to hydrophobic collapse when heated above their transition temperatures  $(T_t)$  and return soluble upon cooling below  $T_t$ (41). As such, thermal transition behaviors of both the copolymer and the polyplexes, as a function of temperature, were monitored by the optical density at 350 nm (OD350). We hypothesized that the addition of a small cationic block, K<sub>8</sub>, to the ELP block, would not greatly alter the transition profile following charge neutralization and polyplex equilibrium. Indeed, as shown in Fig. 5, the block copolymer  $K_{8}$ -ELP(1-60) exhibits a transition temperature of 71.5°C at 25 µM block copolymer concentrations, which was 9.4°C higher than the  $T_t$  of ELP(1-60). Interestingly, when K<sub>8</sub>-ELP(1-60) block copolymers form polyplexes with pDNA, the T<sub>t</sub> decreased to ~45°C with a 1°C  $T_t$  range between 25 and 75% of the maximum absorbance. This behavior was encouraging considering that the copolymer consists of a thermo-insensitive cationic block predicted to alter the phase transition of the putative thermosensitivity of the ELP block. The results indicate that the K8 block promotes a stable and efficient complexation with pDNA. For a thermally responsive gene delivery system to be successful, the copolymer/ pDNA complex should transition within therapeutically relevant temperatures at the therapeutic site and release the pDNA cargo. The thermal transition profile of the complexes depends upon the N/P ratio and exhibits a single transition curve at N/P 1 but evolves into a bimodal curve at N/P>1 with higher N/P ratios approaching the unimodal thermotransitive kinetics of the native cationic elastin diblock copolymer. The bimodal curve suggest two cationic block copolymer populations, copolymers establishing the polyplexes and unbound free copolymer. The thermotransitive uniformity of the complex is critical for successful targeted transfection in terms of higher transfection and lower cytotoxicity. Therefore, the K8-ELP(1-60)/pDNA polyplexes at N/P 1 with a single thermal transition profile are encouraging.

The hallmark of gene therapy is to achieve targeted transgene expression with minimal toxic repercussions; hence, transgene expression and concomitant cytoxocity studies were completed. Concerns of pDNA release were allayed by the heparin displacement assay (Fig. 6) in which the anionic heparin effectively dissociated pDNA from the cationic elastin diblock copolymers. While not a conclusive study, experiments are in-progress to further evaluate the stability of K<sub>8</sub>-ELP(1–60)/pDNA polyplexes by DN*ase* protection. Regarding the transfection efficiency, the K<sub>8</sub>-ELP(1–60)/pDNA polyplexes showed visual, transfection levels relatively less effective than BPEI (Fig. 7), but cytotoxicity remained low (Fig. 8). Most notably, the polyplexes transfected cells at N/P <1 suggesting that ELP-based

cationic block copolymers may undergo cooperative interactions between electrostatic and hydrophobic means during polyplex formation. Based upon these preliminary results we conclude that recombinant cationic diblock copolymers, such as K<sub>8</sub>-ELP(1–60), show tremendous potential as intelligent biosynthetic nanobiomaterials for multiplatform therapeutic applications.

#### CONCLUSION

The overall objective is to create an IBN platform for multimodal gene delivery, drug delivery, and therapeutic fusion proteins. As an extension of IBNs, and based upon the preliminary data, we conclude that recombinant cationic elastic diblock copolymer, K<sub>8</sub>-ELP(1–60), shows tremendous potential for continued development of the IBN platform.

#### ACKNOWLEDGEMENTS

This work was funded by University of Wisconsin-Madison start-up funds to DYF. The ELP(1–30) gene was donated by Prof. Ashutosh Chilkoti (Duke University). We thank Prof. Glen Kwon (University of Wisconsin—Madison) for use of the NICOMP DLS; Prof. Maureen Barr (University of Wisconsin—Madison) for microscope access; and the UW Biotechnology Center for performing MALDI-TOF mass spectrum analysis. We express our thanks to Ms. Tracy P. Williamson for her critical review of the manuscript.

# REFERENCES

- P. Factor. Gene therapy for acute diseases. *Mol. Ther.* 4:515–524 (2001).
- S. Yla-Herttuala and K. Alitalo. Gene transfer as a tool to induce therapeutic vascular growth. *Nat. Med.* 9:694–701 (2003).
- J. T. Santoso, D. C. Tang, S. B. Lane, J. Hung, D. J. Reed, C. Y. Muller, D. P. Carbone, J. A. Lucci 3rd, D. S. Miller, and J. M. Mathis. Adenovirus-based p53 gene therapy in ovarian cancer. *Gynecol. Oncol.* 59:171–178 (1995).
- F. Siddiqui, E. J. Ehrhart, B. Charles, L. Chubb, C. Y. Li, X. Zhang, S. M. Larue, P. R. Avery, M. W. Dewhirst, and R. L. Ullrich. Anti-angiogenic effects of interleukin-12 delivered by a novel hyperthermia induced gene construct. *Int. J. Hyperthermia* 22:587–606 (2006).
- J. Zabner, A. J. Fasbender, T. Moninger, K. A. Poellinger, and M. J. Welsh. Cellular and molecular barriers to gene transfer by a cationic lipid. *J. Biol. Chem.* 270:18997–19007 (1995).
- P. C. Bell, M. Bergsma, I. P. Dolbnya, W. Bras, M. C. Stuart, A. E. Rowan, M. C. Feiters, and J. B. Engberts. Transfection mediated by gemini surfactants: engineered escape from the endosomal compartment. J. Am. Chem. Soc. 125:1551–1558 (2003).
- J. Y. Legendre and F. C. Szoka Jr. Delivery of plasmid DNA into mammalian cell lines using pH-sensitive liposomes: comparison with cationic liposomes. *Pharm. Res.* 9:1235–1242 (1992).
- X. Gao and L. Huang. Cationic liposome-mediated gene transfer. *Gene Ther.* 2:710–722 (1995).
- O. Boussif, F. Lezoualc'h, M. A. Zanta, M. D. Mergny, D. Scherman, B. Demeneix, and J. P. Behr. A versatile vector for gene and oligonucleotide transfer into cells in culture and *in vivo*: polyethylenimine. *Proc. Natl. Acad. Sci. U. S. A.* 92:7297–7301 (1995).
- Z. Megeed, M. Haider, D. Li, B. W. O'Malley Jr, J. Cappello, and H. Ghandehari. *In vitro* and *in vivo* evaluation of recombinant silk-elastinlike hydrogels for cancer gene therapy. *J. Control. Release* 94:433–445 (2004).

#### **IBNs for Hyperthermic Gene Delivery**

- K. Itaka, K. Yamauchi, A. Harada, K. Nakamura, H. Kawaguchi, and K. Kataoka. Polyion complex micelles from plasmid DNA and poly(ethylene glycol)-poly(L-lysine) block copolymer as serum-tolerable polyplex system: physicochemical properties of micelles relevant to gene transfection efficiency. *Biomaterials* 24:4495–4506 (2003).
- D. Fischer, T. Bieber, Y. Li, H. P. Elsasser, and T. Kissel. A novel non-viral vector for DNA delivery based on low molecular weight, branched polyethylenimine: effect of molecular weight on transfection efficiency and cytotoxicity. *Pharm. Res.* 16:1273– 1279 (1999).
- P. van de Wetering, E. E. Moret, N. M. Schuurmans-Nieuwenbroek, M. J. van Steenbergen, and W. E. Hennink. Structure-activity relationships of water-soluble cationic methacrylate/methacrylamide polymers for nonviral gene delivery. *Bioconjug. Chem.* 10:589–597 (1999).
- D. E. Meyer and A. Chilkoti. Genetically encoded synthesis of protein-based polymers with precisely specified molecular weight and sequence by recursive directional ligation: examples from the elastin-like polypeptide system. *Biomacromolecules* 3:357–367 (2002).
- D. W. Lim, K. Trabbic-Carlson, J. A. Mackay, and A. Chilkoti. Improved non-chromatographic purification of a recombinant protein by cationic elastin-like polypeptides. *Biomacromolecules* 8(5):1417–1424 (2007).
- C. Plank, M. X. Tang, A. R. Wolfe, and F. C. Szoka Jr. Branched cationic peptides for gene delivery: role of type and number of cationic residues in formation and *in vitro* activity of DNA polyplexes. *Hum. Gene Ther.* **10**:319–332 (1999).
- D. Fischer, H. Dautzenberg, K. Kunath, and T. Kissel. Poly(diallyldimethylammonium chlorides) and their *N*-methyl-*N*-vinylacetamide copolymer-based DNA-polyplexes: role of molecular weight and charge density in complex formation, stability, and *in vitro* activity. *Int. J. Pharm.* 280:253–269 (2004).
- D. T. McPherson, J. Xu, and D. W. Urry. Product purification by reversible phase transition following *Escherichia coli* expression of genes encoding up to 251 repeats of the elastomeric pentapeptide GVGVP. *Protein Expr. Purif.* **7**:51–57 (1996).
- D. E. Meyer and A. Chilkoti. Purification of recombinant proteins by fusion with thermally-responsive polypeptides. *Nat. Biotechnol.* 17:1112–1115 (1999).
- J. Cappello, J. Crissman, M. Dorman, M. Mikolajczak, G. Textor, M. Marquet, and F. Ferrari. Genetic engineering of structural protein polymers. *Biotechnol. Prog.* 6:198–202 (1990).
- D. W. Urry, T. M. Parker, M. C. Reid, and D. C. Gowda. Biocompatibility of the bioelastic materials, poly(GVGVP) and its γ-irradiation cross-linked matrix: summary of generic biological test results. *J. Bioact. Compat. Poly.* 6:263–282 (1991).
- A. C. Rincon, I. T. Molina-Martinez, B. de Las Heras, M. Alonso, C. Bailez, J. C. Rodriguez-Cabello, and R. Herrero-Vanrell. Biocompatibility of elastin-like polymer poly(VPAVG) microparticles: *in vitro* and *in vivo* studies. *J. Biomed. Mater. Res. A* 78:343–351 (2006).
- D. W. Urry. Physical chemistry of biological free energy transduction as demonstrated by elastic protein-based polymers. *J. Phys. Chem. B* 101:11007–11028 (1997).
- A. Girotti, J. Reguera, F. J. Arias, M. Alonso, A. M. Testera, and J. C. Rodríguez-Cabello. Influence of the molecular weight on the inverse temperature transition of a model genetically engineered elastin-like pH-responsive polymer. *Macromolecules* 37:3396–3400 (2004).
- M. R. Dreher, D. Raucher, N. Balu, O. Michael Colvin, S. M. Ludeman, and A. Chilkoti. Evaluation of an elastin-like polypeptide-doxorubicin conjugate for cancer therapy. *J. Control. Release* 91:31–43 (2003).
- 26. D. Y. Furgeson, M. R. Dreher, and A. Chilkoti. Structural optimization of a "smart" doxorubicin-polypeptide conjugate

for thermally targeted delivery to solid tumors. J. Control. Release 110:362–369 (2006).

- W. Liu, M. R. Dreher, D. Y. Furgeson, K. V. Peixoto, H. Yuan, M. R. Zalutsky, and A. Chilkoti. Tumor accumulation, degradation and pharmacokinetics of elastin-like polypeptides in nude mice. *J. Control. Release* **116**:170–178 (2006).
- D. Raucher and A. Chilkoti. Enhanced uptake of a thermally responsive polypeptide by tumor cells in response to its hyperthermia-mediated phase transition. *Cancer Res.* 61:7163– 7170 (2001).
- G. L. Bidwell 3rd, and D. Raucher. Application of thermally responsive polypeptides directed against c-Myc transcriptional function for cancer therapy. *Mol. Cancer. Ther.* 4:1076–1085 (2005).
- I. Massodi, G. L. Bidwell 3rd, and D. Raucher. Evaluation of cell penetrating peptides fused to elastin-like polypeptide for drug delivery. J. Control. Release 108:396–408 (2005).
- R. Langer and D. A. Tirrell. Designing materials for biology and medicine. *Nature* 428:487–492 (2004).
- A. Aris, J. X. Feliu, A. Knight, C. Coutelle, and A. Villaverde. Exploiting viral cell-targeting abilities in a single polypeptide, non-infectious, recombinant vehicle for integrin-mediated DNA delivery and gene expression. *Biotechnol. Bioeng.* 68:689–696 (2000).
- L. K. Medina-Kauwe, M. Maguire, N. Kasahara, and L. Kedes. Nonviral gene delivery to human breast cancer cells by targeted Ad5 penton proteins. *Gene Ther.* 8:1753–1761 (2001).
- A. Hatefi, Z. Megeed, and H. Ghandehari. Recombinant polymer-protein fusion: a promising approach towards efficient and targeted gene delivery. J. Gene Med. 8:468–476 (2006).
- M. Haider, V. Leung, F. Ferrari, J. Crissman, J. Powell, J. Cappello, and H. Ghandehari. Molecular engineering of silkelastinlike polymers for matrix-mediated gene delivery: biosynthesis and characterization. *Mol. Pharm.* 2:139–150 (2005).
- A. Hatefi, J. Cappello, and H. Ghandehari. Adenoviral gene delivery to solid tumors by recombinant silk-elastinlike protein polymers. *Pharm. Res.* 24:773–779 (2007).
- A. Zintchenko, M. Ogris, and E. Wagner. Temperature dependent gene expression induced by PNIPAM-based copolymers: potential of hyperthermia in gene transfer. *Bioconjug. Chem.* 17:766–772 (2006).
- H. S. Bisht, D. S. Manickam, Y. You, and D. Oupicky. Temperature-controlled properties of DNA complexes with poly(ethylenimine)-graft-poly(*N*-isopropylacrylamide). *Biomacromolecules* 7:1169–1178 (2006).
- P. H. Hirel, M. J. Schmitter, P. Dessen, G. Fayat, and S. Blanquet. Extent of *N*-terminal methionine excision from *Escherichia coli* proteins is governed by the side-chain length of the penultimate amino acid. *Proc. Natl. Acad. Sci. U. S. A.* 86:8247–8251 (1989).
- D. W. Urry. Free energy transduction in polypeptides and proteins based on inverse temperature transitions. *Prog. Biophys. Mol. Biol.* 57:23–57 (1992).
- A. M. Ponce, Z. Vujaskovic, F. Yuan, D. Needham, and M. W. Dewhirst. Hyperthermia mediated liposomal drug delivery. *Int. J. Hyperthermia* 22:205–213 (2006).
- 42. M. Neu, J. Sitterberg, U. Bakowsky, and T. Kissel. Stabilized nanocarriers for plasmids based upon cross-linked poly(ethylene imine). *Biomacromolecules* **7**:3428–3438 (2006).
- D. Putnam, C. A. Gentry, D. W. Pack, and R. Langer. Polymerbased gene delivery with low cytotoxicity by a unique balance of side-chain termini. *Proc. Natl. Acad. Sci. U. S. A.* 98:1200–1205 (2001).
- K. L. Kiick, E. Saxon, D. A. Tirrell, and C. R. Bertozzi. Incorporation of azides into recombinant proteins for chemoselective modification by the Staudinger ligation. *Proc. Natl. Acad. Sci. U. S. A.* 99:19–24 (2002).